17th Symposium on COVID-19: What Have We Learned? How Can We Use What We Have Learned? – Touro College News

An online webinar, the 17th Coronavirus (COVID-19) Symposium is sponsored byNew York Medical Collegeof the Touro College and University System. Continuing Medical Education credits are available upon request.

A presentation by the Center for Disaster Medicine of New York Medical College of the Touro College and University System.

by Edward C. Halperin, M.D., M.A.Chancellor and CEO, Professor of Radiation Oncology, Pediatrics and History, New York Medical College | Provost for Biomedical Affairs, Touro College and University System

byRobert Amler, M.D., MBADean, School of Health Sciences and Practice, Vice President for Government Affairs, New York Medical College | Former Regional Health Administrator, U.S. Dpartment of Health and Human Services | Former Medical Epidemiologist, Centers for Disease Control and Prevention (CDC)

by Marisa A Montecalvo, M.D.Medical Director, Health Services, New York Medical College | Infectious Disease Specialist

byMill Etienne, M.D., M.P.H., FAAN, FAESVice Chancellor for Diversity and Inclusion, Associate Dean for Student Affairs, Associate Professor of Neurology and Medicine, School of Medicine House Advisory Dean, New York Medical College

byTami Hendriksz, DO, FACOP, FAAPDean and Chief Academic Officer, Professor of Pediatrics, Touro University California College of Osteopathic Medicine

byDaniel ShallitDirector of Global Store Development for New York City, Long Island and New Jersey, Starbucks and Princi Italian Bakery Real Estate/Development | Co-Chair of the Real Estate Entrepreneurship Advisory Board, Touro College Graduate School of Business

Hosted by Alan Kadish, M.D.Cardiologist | President, Touro College and University System | President, New York Medical College

Responses will be provided to the questions submitted in advance of the webinar. Questions may be submitted tocovid19updates@touro.edu

Register in advance for the webinar

This meeting has been approved for 1.5 CME credits by the Office of Continuing Medical Education, New York Medical College free of charge as a community service to our Healthcare Providers.

Accreditation Statement:New York Medical College is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Target Audience:Hospital-based physicians; Community physicians; Nurses; Pharmacists; Medical Students; Residents/Fellows; Public Health; Other Healthcare Providers; and Press.

Credit Designation:The New York Medical College designates this live activity for a maximum of 1.5AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement:All activity faculty and planners participating in continuing medical education activities provided by New York Medical College are expected to disclose to the audience any significant support or substantial relationship(s) with commercial entities whose products are discussed in their presentation and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in their presentations.

Commercial Support:There is no outside funding for this activity.

See original here:
17th Symposium on COVID-19: What Have We Learned? How Can We Use What We Have Learned? - Touro College News

Dr. Bruce T. Liang Named Interim CEO of UConn Health – UConn Today – UConn Today

On Thursday, Jan. 27 the UConn Health Board of Directors held a special meeting to endorse the Universitys appointment of Dr. Bruce T. Liang as UConn Healths Interim CEO and Executive Vice President of Health Affairs. His appointment is effective Feb. 1.

He will serve as successor to Dr. Andrew Agwunobi, CEO of UConn Health since 2015, who will assist with the transition until he leaves later in February for a new position in private industry.

I am humbled and honored to be asked to serve as the Interim CEO of UConn Health and with the privilege to work with our Interim President Dr. Radenka Maric, Liang told the board.

Liang is an internationally recognized cardiovascular physician-scientist and national leader in academic medicine. He will continue to serve as dean of UConn School of Medicine and the Ray Neag Distinguished Professor of Cardiovascular Biology and Medicine. Liang first joined UConn Health in 2002 as a physician-scientist faculty member and was appointed dean of the medical school in 2015. As dean he has led to new heights UConns advancement of medicine, medical education, and research.

The board has come to know Dr. Liang over the last many years. We know of his great talent, vision and commitment to the mission of the medical school as well as UConn Health, said Sanford Cloud, Jr., chairman of the UConn Health Board of Directors. He is well-qualified to be named interim executive vice president.

Liang shared his excitement to have the opportunity to work more broadly with such excellent leaders at UConn Health and its Schools.

I hope to fulfill the great potential and promise of UConn Health, Liang said. We will strive to advance the very positive trajectory in our tripartite missions of excellence in quality and safety of clinical care, of continuing growth as the single-largest source of physicians, dentists, surgeons, and public health experts for the state of Connecticut. Also, continue to grow as a science and innovation hub in collaboration with our colleagues at UConn Storrs, the School of Dental Medicine, and our close partner The Jackson Laboratory.

We will also advance the missions of community collaboration with our faculty, staff, and students who provide valuable volunteer services ranging from vaccination collaborations with community healthcare workersto serving the underserved communities.

During the special meeting, Cloud also thanked departing CEO Agwunobi for his exemplary service to UConn Health.

Andy, we all want to thank you for your outstanding leadership over the last several years. You have led the transformation of UConn Health in every way, including its growth. You have been an extraordinary leader. We wish you the very best, said Cloud.

Andy leaves behind a very, very powerful legacy here, said UConn Board of Trustees Chairman Daniel Toscano.

I am grateful to Dr. Andy for his transformative leadership at UConn Health, Liang said.

In 2021, Liang led the School of Medicines 50th anniversary celebration of its generational community impact in producing five decades of new physicians, surgeons, scientists, and community leaders to serve the state of Connecticut and beyond while increasing diversity and health equity in academic medicine. In fact, U.S. News & World Report has named it as one of the 10 most diverse medical schools in the nation, as 23% of its student body are from underrepresented groups in medicine.

Under Liangs leadership the medical school has received record-breaking research grant funding of over $100 million year after year. He also has overseen the schools successful implementation of a new-age, team-based and patient-centered four-year curriculum since 2016, better preparing future physicians for the rapidly evolving health care field. In fact, UConn was the first medical school in the nation to eliminate lectures, and continues to offer early, hands-on clinical care exposure at the very start of medical school, along with the integration of basic sciences education. The school also has completed several successful LCME accreditation surveys under Liangs leadership, and is highly ranked nationally among public medical schools as No. 30 in primary care and No. 31 in research by U.S. News & World Report.

As an active researcher, Liangs cutting-edge translational research contributions have advanced scientific knowledge about heart disease. His research has been continuously funded since 1986 by the NIH, the American Heart Association, and the US Department of Defense. He is widely published in the areas of cardiac myocyte, intact heart biology, and heart failure translational research. His latest research investigations have developed a new potential medication for advanced heart failure patients. This research, jointly performed with scientists at the NIH, has received patents from the United States and European Union.

Liang is a fellow of the American Association for the Advancement of Science (AAAS), American College of Cardiology, and the American Heart Association, and is an elected member of the American Society for Clinical Investigation, the Association of University Cardiologists, the Council on Clinical Cardiology and Basic Cardiovascular Sciences, and the Connecticut Academy of Science and Engineering. He has been consistently named one of Americas Top Doctors and Best Doctors in America for cardiovascular disease care.

Prior to joining UConn Health in 2002, for 13 years he served the University of Pennsylvania School of Medicine as associate professor of medicine and pharmacology. Liang received his bachelors degree from Harvard in biochemistry and molecular biology and his medical degree from Harvard Medical College. He completed his internal medicine internship and residency training at the Hospital of the University of Pennsylvania and cardiology fellowship training at Brigham and Womens Hospital and Harvard Medical School.

See the article here:
Dr. Bruce T. Liang Named Interim CEO of UConn Health - UConn Today - UConn Today

UMass Chan Medical School offering $25 gift cards for participation in COVID at-home test study – MassLive.com

People taking at-home COVID-19 tests now have the chance to get paid for it thanks to a University of Massachusetts Chan Medical School study.

The study will look at the performance of new at-home tests, according to Sarah Willey, a spokesperson for the school.

Researchers are hoping to enroll 1,300 participants, to obtain a minimum number of results that test positive for disease, she said.

Participants will have to download the MyDataHelps app, answer questions and perform three types of COVID-19 tests at home over one to two days, according to Willey.

The tests will be provided at no costs and once participants use them, they will have to mail their sample to a lab for PCR testing.

Once all the steps are completed the participants will be provided with a standard $25 gift card, Willey said.

Anyone in the U.S. over the age of two can participate, except those in Arizona due to lab limitations.

Participants will receive their results two to five days after shipping, according to Willey.

The study is part of the RADx digital Independent Test Assessment Program (ITAP), which helps researchers confirm the performance of new rapid antigen testing, as they seek to bring more high-quality tests to market, Willey said.

UMass Chan researchers have also evaluated the impact of the SayYes! COVID Test program in Michigan where 500,000 free at-home rapid antigen tests were distributed to residents of Ann Arbor and Ypsilanti in the summer of 2021.

According to the study, which has not been peer-reviewed, during the delta variant surge two months after the program, infection rates were significantly lower in the cities that received the at-home tests.

Its clear that at-home rapid antigen tests are useful, and they have tremendous value at an individual level in terms of how people decide to live their lives in the pandemic, but also provide invaluable information to experts at a population health level, Dr. Apurv Soni, assistant professor of medicine at UMass Chan and principal investigator on the study.

Soni is also the principal investigator for this latest at-home test study.

Anyone interested in participating can download the MyDataHelps app to sign up.

Related Content:

See original here:
UMass Chan Medical School offering $25 gift cards for participation in COVID at-home test study - MassLive.com

FTC announces settlement with for-profit medical school alleged to have engaged in deceptive marketing – Consumer Finance Monitor

The FTC has announced a stipulated order of judgment in a lawsuit that it recently filed against Saint James School of Medicine, a for-profit medical school located in the Caribbean, together with its operator and financiers. The $1.2 million judgment will be used toward refunds and debt cancellation for students who financed their education within the past five years.

In its complaint, the FTC alleged that Saint James and its operators violated the FTC Act, the TSR, the Holder Rule, and the Credit Practices Rule. The FTC specifically alleged that Saint James lured consumers with false guarantees of student success, and made false or unsubstantiated representations regarding potential students likelihood of matching into residency programs upon graduation The FTC further alleged that the Defendants financing contracts contain language attempting to waive consumers rights under federal law and omit legally-mandated disclosures.

According to the FTC, Saint James misrepresented the Medical License Exam Pass Rate, claiming 96.77% FIRST TIME USMLE STEP 1 PASS RATE. The FTC alleged that since 2017, only 35% of Saint James students who have completed the necessary coursework passed the USMLE Step 1 exam. The FTC also alleged that Saint James misrepresented the residency match rate, the percentage of medical school seniors who are accepted for residencies, stating Saint James falsely advertised their residency match rate was 83% (since 2018, the average match rate for Saint James students has been 63%).

With regard to Saint James financers, the FTC alleged that the financing contracts did not include federally required language under the Holder Rule and failed to provide the cosigners with the required Notice to Cosigner.

The proposed judgment also requires Saint James and its co-defendants to request tradeline deletion from consumer reporting agencies for Saint James students who financed their education through the corporate defendants within the past five years. The judgment prohibits Saint James and its financers from continuing the alleged misrepresentations and engaging in further violations of law. Additionally, the judgment permanently restrains and enjoins the defendants from extending credit to a consumer unless the Notice to Cosigner Disclosure [] has been given to the cosigner prior to becoming obligated.

In response to the FTCs announcement of the proposed judgment, the director of Saint James issued a statement explaining the schools decision to enter into a settlement despite its strong disagreement with the FTCs approach. The director stated:

[W]e did not want a lengthy legal process to distract from our mission of providing a quality medical education at an affordable cost. However, we have added additional language and clarifications any time the USMLE pass rate and placement rates are mentioned. We are committed to being an industry leader for transparency and accountability and hope that our efforts will lead to lasting change throughout the for-profit education industry.

See the rest here:
FTC announces settlement with for-profit medical school alleged to have engaged in deceptive marketing - Consumer Finance Monitor

Should medical errors be criminalized? This Fort Worth medical school offers another way – KERA News

Vanderbilt nurse RaDonda Vaught was chatting with a mentee the day after Christmas in 2017 when she typed the first two letters of her patients prescription into the drug cabinet monitor: V-E.

She wanted Versed, a sedative to help the 75-year-old patient a woman hospitalized for a brain bleed relax before her final scan. Instead, she selected vecuronium, a drug that causes paralysis. Vecuronium was Vaughts top search result, and she didnt check the label before administering it.

Within the hour, her patient had no pulse. In fewer than 12, she had died. Later, the patients medical examiner report would identify her cause of death: acute vecuronium intoxication, an error for which Vaught would, just last month, be criminalized.

In the decades since patient safety surfaced as a research priority, no official count of accidental patient deaths exists, but some experts estimate the number in the U.S. could be in the hundreds of thousands each year. The system is not improving, said Lillee Gelinas, a nurse and course director for patient safety at the Texas College of Osteopathic Medicine. And you have to back up and say, Why?

Since 2019, before Vaughts conviction swept national headlines, Gelinas and her colleagues at the medical school have worked to answer that question. One solution, she said, is academic which is why, in 2020, the Texas College of Osteopathic Medicine became the only medical school in the world to require its students to take the internationally recognized Certified Professional in Patient Safety exam.

At the end of the day, we are committed to developing safe providers of the future, she said. Its our responsibility and accountability to our community.

An epidemic of preventable harm

The second chapter of the seminal report, To Err is Human: Building a Safer Health System begins somberly: Health care is not as safe as it should be.

The 1999 report, published by the organization now known as the National Academy of Medicine, estimated that as many as 98,000 hospitalized Americans die each year from medical errors. The insights galvanized the patient safety movement as we know it today, Gelinas said.

More recent studies expand those estimates. In 2016, an analysis from Johns Hopkins University School of Medicine suggested that number could be more than 250,000 people each year, making medical error the third leading cause of death in the U.S. before the pandemic.

The uncertainty comes, in part, from the continued lack of a nationwide reporting system, which the To Err is Human report recommended. By 2015, just over half of the states, including Texas, required hospitals but not necessarily clinics or outpatient providers to report preventable harm.

The bottom line: The amount of preventable harm and death is too many, Gelinas said. Her boss and the dean of the Texas College of Osteopathic Medicine, Dr. Frank Filipetto, calls it an epidemic.

Were carrying germs from patient to patient

Dr. Conner Reynolds was scribing for an emergency room physician in Waco when he noticed the physicians smartphone.

He would remove it from his pocket for every patient, calculating risk scores and checking treatment options first for the diarrhea patient, then the stroke patient, then the heart attack patient. Following protocol, the physician would wash his hands in between, but he didnt clean his phone.

Were carrying germs from patient to patient, Reynolds pointed out. He and the physician looked at each other. Is this OK? Is this something we need to consider?

The question led Reynolds, who was in college at the time, to pursue a research study on health care student cell phone use when he enrolled at the Texas College of Osteopathic Medicine. The results reflected his physicians behavior: Overall, health care students were likely to use their phones in the restroom and wash their hands afterward; however, they cleaned their phones less than once a week.

Reynolds, along with Gelinas, presented the research at the Institute for Healthcare Improvements national conference in late 2018. There, he learned about the Certified Professional in Patient Safety credential, an accolade that could only be earned by health professionals with three to five years of direct clinical experience under their belts.

The criteria excluded medical students, who typically start clinical rotations in year three and therefore wouldnt be eligible to sit for the exam until at least their second year in residency.

And we all sort of sat down and asked ourselves, Why in the world would we want to send providers out into health care, let them learn bad habits and then, five years later, teach them the right way to do things? Reynolds remembers.

He calls it a Eureka moment, and it aligned with the hiring of Filipetto, a staunch patient safety advocate, as dean of the medical school.

Tools to identify when theres problems in the system

The day after Filipetto had his tonsils removed as a 6-year-old, he felt something strange in the back of his throat. It was a piece of gauze, unintentionally left behind, and he started choking on it.

That was terrifying, he remembers. My parents didnt know what to do. Luckily, I was able to cough it up after a minute or two, but that was what we would call a near-miss.

Years later, when he was applying to become dean, patient safety was part of his platform. We know that people make mistakes. Theyre not intentional, he said. Its impossible to prevent human error, but how do we create a system whereby the system either catches that or where bad outcomes dont occur?

The patient safety component was part of a larger curriculum shift Filipetto had advocated: the inclusion of health systems science to a traditional spate of courses like anatomy and clinical skills. Health systems science takes a birds-eye view of health care delivery, requiring a critical look at how health professionals work together.

You want a (medical) student thats a systems thinker, that doesnt just think siloed You also want somebody that has an open mindset, said Dr. Janet Lieto, who directs the health systems science curriculum at the medical school.

After the Eureka moment, Lieto and Gelinas set to work creating a patient safety course for the schools medical students. Their first priority: collaborating with the Institute for Healthcare Improvement, an organization that provides educational resources for the Certified Professional in Patient Safety exam.

To prove that medical students could, indeed, pass the exam before three years of clinical experience, they received permission from the Certification Board to pilot a patient safety course with 10 students nine of whom passed the exam on the first try. The national average is 70%.

Texas College of Osteopathic Medicine

/

Once the Institute for Healthcare Improvement and the Certification Board gave the go-ahead, the college received the necessary approvals to incorporate patient safety into the schools curriculum. Less than two years after the Eureka moment, in July 2020, the Texas College of Osteopathic Medicine became the only medical school in the world that requires its students to take the patient safety certification exam before graduating.

The Institute for Healthcare Improvement tracks data on every person who has passed the exam, a spokesperson told the Fort Worth Report. She confirmed the Texas College of Osteopathic Medicines globally unique status.

On the institutes website, Texas list of certified professionals vastly overshadows that of other states. After nearly 500 medical students have taken the patient safety course, the schools pass rate is 98%.

The course itself spans just two weeks, about eight hours a day, during a medical students third year, Gelinas said. The cost to each student, which covers the training materials and the exam, is about $900. When they pass the exam, students can add C.P.P.S. to their white coats.

When Reynolds, who passed the exam in 2021, applied for residency programs, the initials came up again and again in his interviews. Now, as a resident at JPS Health Network, hes helping his colleagues develop safer systems to protect their patients.

The initials after the name isnt the most important thing, Lieto said. The most important thing is giving them those tools to identify when theres problems in the system.

We can eliminate preventable death

Charlene Murpheys head ached when she checked into the emergency room at Vanderbilt University Medical Center in Nashville, Tennessee. It was Christmas Eve 2017, and Murphey had been shopping earlier that day, according to a Centers for Medicare & Medicaid Services report.

The 75-year-old lived about 30 miles away, in a suburb called Gallatin, and had had her share of health troubles: Guillain-Barre syndrome, lupus and breast cancer, but her prognosis looked hopeful. A CT image revealed bleeding in her brain, but her condition improved, and by Dec. 26, she was almost ready to leave. Before her final scan, Murphey mentioned she was claustrophobic, and her physician prescribed Versed to calm her nerves.

Months after Murphey died from vecuronium intoxication, the Centers for Medicare & Medicaid paid Vanderbilt University Medical Center a surprise visit.

Inspectors found the hospitals policies lacked guidance about when and how to monitor patients after administering high-alert drugs like vecuronium. The report also determined the hospital lacked adequate safety measures to prevent providers from accidentally acquiring such medicines from the drug cabinet. Finally, the hospital had not reported the error to the Tennessee Department of Health, a requirement by state law.

So when people talk about safety, I worry that they just see that (Vaught) made this mistake, Lieto said. You have to ask why and when you come down to it, its usually a system error or a process error in addition to a human error. And thats the piece that people forget about.

Vaughts criminal conviction in late March undercuts a key component of patient safety, Gelinas said: Just culture, or an environment where people feel safe to discuss mistakes without fear of punishment. This one case, the criminalization of medical error, has really put a chilling effect on a lot of the progress that weve made, she said.

A patient safety course like the one at the Texas College of Osteopathic Medicine acknowledges that, while people make mistakes, good systems can prevent bad outcomes. Gelinas hopes more and more medical schools come to adopt a similar strategy; she and Lieto are scheduled to present their success at the Institute for Healthcare Improvements Patient Safety Congress in May.

So long as it involves humans, health care will never be free of errors, she said. But it can be free of preventable death.

Whats the problem?

Although no official count of accidental patient deaths exists, some experts estimate the number in the U.S. could be in the hundreds of thousands each year.

Whats a possible solution?

Since 2020, the Texas College of Osteopathic Medicine has required its medical students to take a patient safety course and the Certified Professional in Patient Safety exam before graduating. The requirement involves a collaboration between the school and the Institute for Healthcare Improvement.

Continued here:
Should medical errors be criminalized? This Fort Worth medical school offers another way - KERA News

New exhibit takes Urban Arts Space visitors ‘Behind the White Coat’ – Columbus Alive

Elizabeth Auckleys early interest in science convinced her she wanted to become a doctor, but she also loved visual art. Auckley took painting classes in high school, and in college at Ohio State, she added an art history major while taking pre-med courses. It scratched the arts itch a bit, but she didnt create anything herself duringthose undergrad years.

Auckley remained at Ohio State for medical school, and it was there she discovered Humanism in Medicine, a student-led organization that recognizes the humanities as an essential part of medical practice studies.

I think medicine is an art in itself, so having some kind of artistic background, it really becomes part of your medical practice, said Auckley, a third-year student at OSUs College of Medicine. Thinking about medical education, it's such a jam-packed four years, and there's a lot to learn here. It's a very rigorous curriculum, so there's always the argument that if you're adding in humanities education, are you taking out some valuable science portion?

A lot of the 20th century medical education ideas about medicine removed the humanities aspect and just focused on diseases as an organ system, separating the personalization of disease. Now, we think that really was not the right way to do things. So the focus of the 21st century is moving medicine back to more of a balance keeping the humanities side of personalization and deconstructing the hierarchy of the physician-patient relationship.

Through Humanism in Medicine, Auckley met Phillip Anjum, a fourth-year medical student, videographer and photographer. Anjum approached Auckley with a collaborative concept. His idea was to take portraits of our classmates in a setting outside of medicine, showing how they like to spend their time, what they identify with as a person, not as a medical student, said Auckley, who would then add paint to Anjums canvas-printed, black and white photos. "He wanted me to paint the color back in over the prints as a symbol of the personalization and the complexity of each person, really highlighting who they are outside of medicine.

From 2020 through March of 2022, Auckley and Anjum worked together on the project, and today (Tuesday, April 26), theircollaboration debuts at OSUs Urban Arts Space Downtown. Titled Behind the White Coat, the exhibition runs through May 7.

Anjum and Auckley wanted to use translucent layers of paint, a technique that usually calls for watercolor, which doesnt work well on canvas. So instead, Auckley tried a new method of thinning oil paint to create a similar effect. I ended up putting washes on each portraitin the style of watercolor, but with oil paint, she said. There's an old saying that your painting is only as good as the drawing. Painting is really my love; I'm OK at drawing, but it's not what I love to do. This project took away the drawing aspect. I was basically given a stencil Phil's beautiful photographs.

The project also gave Auckley newfound confidence and a reignited fire for making art, even during medical school. I really didn't think that I would come back to art [now]. I thought it probably would be later down the line when I have more time in my career or when I retired, she said. Having it in a gallery like this is unimaginable. … I'm glad I got some courage built up in me to do it.

Auckley also hopes the exhibition, and the ideas behind it, can benefit other students and the medical profession as a whole. Physician burnout and stress a lot of that arcs back to how your medical school experience was, she said. We hope that by showing these portraits, we can encourage people to live their lives as who they are and still enjoy their hobbies and their personal lives and families and friends, and realize that's a part of everyone's lives and not something that you have to hide.

See more here:
New exhibit takes Urban Arts Space visitors 'Behind the White Coat' - Columbus Alive

Perelman School of Medicine 2022 Teaching Awards | University of Pennsylvania Almanac – Almanac

Perelman School of Medicine 2022 Teaching Awards Deans Award for Excellence in Clinical Teaching (at an Affiliated Hospital)

The Deans Award for Excellence in Clinical Teaching was established in 1989 to recognize clinical teaching excellence and commitment to medical education by outstanding faculty members from affiliated hospitals. One or more Deans Awards are given annually, the recipients being selected on the advice of a committee composed of faculty and students.

Judd Flesch is an assistant professor of clinical medicine in the department of medicines division of pulmonary, allergy, and critical care. He graduated from the Perelman School of Medicine in 2006 and subsequently completed his internal medicine residency, chief residency, and pulmonary/critical care fellowship at the Hospital of the University of Pennsylvania. During his fellowship, he also served as the Mayock Chief Fellow. He joined Penns faculty in January 2014 and has served as an associate program director of the Internal Medicine Residency Program and site director at Penn Presbyterian Medical Center (PPMC) for the past eight years. In addition to overseeing clinical rotations at PPMC, Dr. Flesch also oversees the mentorship program for residents. He is passionate about clinical teaching, working with residents, fellows, and medical students in both inpatient and outpatient settings. In addition to his educational roles, Dr. Flesch is active in clinical operations leadership at PPMC, serves on the department of medicine Professionalism Committee, and is the co-director of the Penn Medicine Program for LGBTQ Health.

Temitayo Ogunleye is an associate professor of clinical dermatology and the associate director of diversity, equity, and inclusion in the department of dermatology. She received her medical degree from the Perelman School of Medicine, completed her residency training in dermatology at the University of Michigan, and trained at the University of Pennsylvania as a clinician educator fellow to further her interests in medical education and develop her current niches of skin color and hair disorders. Dr. Ogunleye received a masters degree in healthcare innovation from Penn in 2021 and was appointed as medical director of the dermatology clinic at the Perelman Center for Advanced Medicine in January 2022. She plays an active role in medical education, interacting with both medical students and residents in her clinics and on inpatient consultations at Penn Presbyterian Medical Center. She is a member of her departments Clinical Competency Committee and serves as a GME Ombudsperson. She is also a faculty leader of the Faculty Forums committee of the Alliance of Minority Physicians, a resident-led organization comprised of residents, fellows, and attending physicians who are underrepresented in medicine and committed to creating a diverse workforce. A former trainee commented, (she) is simply the best. She is kind, courteous, charismatic. She is a great teacher andI love working with her.

Carla R. Scanzello is an associate professor of medicine in the division of rheumatology at the Perelman School of Medicine, and section chief of rheumatology at the Corporal Michael J. Crescenz VA Medical Center (CMCVAMC) in Philadelphia. Dr. Scanzello received her medical and graduate degrees from Temple University School of Medicine in Philadelphia, completed her residency training at New York-Presbyterian/Weill Cornell Medical Center, and her rheumatology fellowship at the Hospital for Special Surgery in New York. She joined Penn and the CMCVAMC in 2013, where she established a laboratory focused on osteoarthritis therapeutic development within the Translational Musculoskeletal Research Center, which she now co-directs. In addition to her research pursuits, she is dedicated to education of clinical trainees. She regularly supervises rheumatology fellows in their weekly VA clinics and participates as a faculty member in PSOMs Cell & Tissue Biology and Mechanisms of Disease and Therapeutic Interventions courses. She teaches medical students and trainees from multiple specialties and primary care rotating through the rheumatology clinics at the CMCVAMC. This includes bedside teaching within the CMCVAMC Multi-Disciplinary Osteoarthritis Clinic, which she co-established. In partnership with colleagues in endocrinology and radiology, she co-organizes quarterly conferences in metabolic bone disorders for trainees at the CMCVAMC. In all these settings, she encourages trainees to set educational goals for themselves to foster a lifetime of self-directed learning and to collaboratively engage colleagues from other specialties to optimize inter-disciplinary care for patients. As former trainees have commented, Dr. Scanzello is an outstanding teacher. She regularly helps fellows develop learning goals and then revisits these to check in on progress. I appreciate that she takes into account my learning goals and actively incorporates these into her teaching styleShe is a great role model as a rheumatologist.

Nicole Washington is an assistant professor of clinical pediatrics within the department of pediatrics at the Perelman School of Medicine and an attending physician with the division of general pediatrics at the Childrens Hospital of Philadelphia (CHOP). Dr. Washington received her BA in Spanish and her medical doctorate from the University of Virginia. She completed her pediatric residency training at CHOP. After completing her residency, she served as a pediatric chief resident for the hospital and the pediatric residency program. Dr. Washington remains active in the pediatric residency program, serving as one of the associate program directors and an integral member of the Intern Selection Committee; she also is currently the chair of the American Board of Pediatrics Education and Training Committee. Dr. Washington is one of the faculty mentors of the Alliance of Minority Physicians, a resident-led organization at CHOP comprised of residents, fellows, and attending physicians who are underrepresented in medicine and committed to creating a diverse workforce. Dr. Washington has mentored countless residents, medical students, and undergraduate students with a strong dedication to ensuring their personal and professional growth. Dr. Washington is also committed to her own professional growth and improvement, and is currently enrolled in the College of Liberal & Professional Studies Master in Organizational Dynamics Program. She plans to share this new knowledge and growing expertise with her trainees to further their leadership development.

This award was established by the department of anesthesia in 1984. As a pioneer in the specialty of anesthesia and chair of the department from 1943 to 1972, Dr. Dripps was instrumental in the training of more than 300 residents and fellows, many of whom went on to chair other departments. This award is to recognize excellence as an educator of residents and fellows in clinical care, research, teaching, or administration.

David Aizenberg is an associate professor of clinical medicine in the division of general internal medicine. He came to Penn in 2007 as an intern and stayed on to complete his residency and a chief resident year. He then joined the faculty and continued to have an active role within the internal medicine residency. Dr. Aizenberg enjoys optimizing learning environments and has led several educational innovations, including transitioning the program into a block scheduling system and designing and implementing a theme-based ambulatory curriculum. In 2018, Dr. Aizenberg left Penn to lead the Drexel/Hahnemann University Hospital internal medicine residency as its program director. During the unexpected closure of Hahnemann, Dr. Aizenberg advocated on behalf of all the residents and fellows impacted by this crisis and helped them to find receiving programs. Dr. Aizenberg returned to Penn in 2020 and joined the GME leadership team as director of assessment and professional development. In this role, he helps programs improve their assessment systems and coaches struggling housestaff. Dr. Aizenberg continues to be clinically active in outpatient primary care and the inpatient wards at PPMC.

Created in 1987 by the Blockley Section of the Philadelphia College of Physicians, this award is given annually to a member of the faculty at an affiliated hospital for excellence in teaching modern clinical medicine at the bedside in the tradition of William Osler and others who taught at Philadelphia General Hospital.

Sean Harbison is a native Philadelphian, having spent almost his entire education and professional career within blocks of Broad Street. After earning his BA in biology from LaSalle College, Dr. Harbison attended Temple University School of Medicine and completed general surgery training at the Graduate Hospital and at Memorial Sloan Kettering Cancer Center in New York. He has served as a faculty attending surgeon and professor of surgery at Graduate Hospital, Temple University Hospital and, most recently, in the department of surgery at the Perelman School of Medicine, where he focuses on educational roles at each institution. For the past 8 years he has served as an associate clerkship and sub-internship director in the department of surgery, and he recently earned a masters degree in medical education from Penn. He has had his teaching prowess recognized by multiple teaching awards, including induction into AOA Medical Honor Society (2005), three Penn Pearl Awards (1995, 2017, 2021), and the Deans Award for Clinical Teaching (1997). A former student stated, I hope to emulate your style with patients and students when Im a physician: Thank you for making me feel like a valued team-member and [for] an inspired learning experience.

This award was established in 1981 as a memorial to Leonard Berwick by his family and the department of pathology. It recognizes a member of the medical faculty who in his or her teaching effectively fuses basic science and clinical medicine. It is intended that this award recognize persons who are outstanding teachers, particularly among younger faculty.

Katharine Bar is an assistant professor of medicine in the division of infectious diseases and a physician-scientist studying novel approaches to HIV prevention and cure. Her translational research program fuses a virology laboratory studying the basic mechanisms of viral pathogenesis with clinical trials of HIV and SARS-CoV-2 interventions. Dr. Bar is an engaged teacher in both her clinical and research roles at Penn and through her leadership in national scientific organizations. She precepts medical trainees and leads multiple small group sessions for medical students, internal medicine residents, and infectious disease fellows. She is also an active teacher of cell and molecular biology graduate students, for whom she co-directs a journal club format class centered on HIV. Through her laboratory, she serves as a formal mentor for multiple students and an informal mentor to many additional trainees, in particular women pursuing basic and translational research careers. Outside of Penn, she is known as a dynamic speaker who communicates complex concepts in an engaging manner. A physician-scientist trainee mentored by Dr. Bar wrote, Dr. Bar has consistently mentored me through graduate and clinical phases of my development as a physician-scientist, always reminding me of the duality of my training. I have witnessed Dr. Bars tailored mentorship of numerous friends who are graduate students, medical trainees, and budding physician-scientists. She assesses a mentees needs and meets them at their level. Her advice is honest, thoughtful, and based on her wealth of experience as a successful physician-scientist.

This award was established in 2000 by the Penn/VA Center for Studies of Addiction and the department of psychiatry. Scott Mackler is known for his excellence in teaching medical students, residents, post-doctoral fellows, nurses, and other Penn faculty in many different departments in the area of substance abuse.

Subhajit Chakravorty is an assistant professor of psychiatry at the Perelman School of Medicine and a staff physician at the affiliated Corporal Michael J. Crescenz Veterans Affairs Medical Center (CMCVAMC). He completed his medical school training at the University College of Medical Sciences, Delhi, India. He trained in psychiatry at the University of Pittsburgh and completed his sleep medicine training and a master of science in translational research at the University of Pennsylvania. In addition, he completed his addiction research and clinical care fellowship at the affiliated CMCVAMC. He is certified in psychiatry, sleep medicine, and addiction medicine. He attends to patients in sleep medicine at the Hospital of the University of Pennsylvania and addiction psychiatry at CMCVAMC.

His program of research focuses on developing personalized treatment interventions for insomnia comorbid with alcohol use disorder and their underlying mechanisms for change. Additionally, he is interested in understanding how alcohol use interfaces with sleep-related disorders.

The Deans Award for Excellence in Basic Science Teaching was established in 1988 to recognize teaching excellence and commitment to medical student teaching in the basic sciences. One or more Deans Awards are given annually, the recipients being selected on the advice of a committee comprised of faculty and students.

Rahul Kohli is an associate professor of medicine in the division of infectious disease, with a secondary appointment in the department of biochemistry and biophysics. Dr. Kohli obtained his MD and PhD from Harvard Medical School, after which he completed his internal medicine residency at Penn and his post-doctoral fellowship and clinical infectious disease training at Johns Hopkins University. The chief objective of his research group has been to probe DNA modifying enzymes and using approaches rooted in enzymology and chemical biology. The enzymes targeted by his groups studies catalyze the purposeful modification of the genome and are central to host-pathogen interactions or to epigenetics. Dr. Kohlis work has been recognized through support from the Burroughs Wellcome Fund, the Doris Duke Foundation, the Rita Allen Foundation and an NIH Directors New Innovator Award, among others. He has been elected to the American Society for Clinical Investigators (ASCI) and has received the American Chemical Society (ACS) Pfizer Award in Enzyme Chemistry. At Penn, Dr. Kohli is dedicated to the mission of training the next generation of physician-scientists grounded in basic science. Since 2014, he has served as an associate program director of the Penn MD/PhD program. His roles in the program include supporting combined degree students in the Biochemistry and Molecular Biophysics Graduate Group and being the course director for Topics in Molecular Medicine, a course aimed at introducing all first-year combined degree students to cutting edge basic science work with medical implications.

This award was established in 1997 to recognize outstanding teaching by allied health professionals (e.g.; nurses, physicians assistants, emergency medical technicians). The recipient is selected on the advice of a committee composed of faculty and students.

Michelle Jackson has nearly 15 years of experience as a clinician working in the field of individual, couple, and family therapy. She holds a BA in womens studies and philosophy from Temple University and an MSS in clinical social work from the Bryn Mawr College Graduate School of Social Work and Social Research. Currently, Ms. Jackson is an attending faculty member in the Psychiatry Residency Assessment Clinic for third-year residents at Penn. She adds family and systems perspectives to the overall discussion of patients presenting for care and also ensures that residents consider race, gender, sexual orientation, social class, and cultural background for all of their new and on-going patients. Ms. Jackson was on the clinical faculty of the Center for Couples and Adult Families in the department of psychiatry at Penn Medicine until 2019. In that position, she collaborated with the clinical director and other colleagues to provide therapy for a wide variety of family life cycle transitions, adjustment and mood disorders, and relationship concerns. In addition to her work at Penn, Ms. Jackson has been a valued instructor for undergraduate, graduate, and post-graduate students since 2014. She has taught in the department of psychology at Philadelphia University (now part of Thomas Jefferson University), in the Rutgers University School of Social Work, in the Couple and Family Therapy program at Thomas Jefferson University, and in the post-graduate certificate program at Council for Relationships. Known for her enthusiasm and dynamism in the classroom, Ms. Jackson is sought after as a student advisor, professional mentor, and clinical supervisor.

This award was established in 2015 to recognize clinical teaching excellence and commitment to medical education by outstanding housestaff. One award is given annually. The recipient is selected on the advice of a committee composed of faculty and students.

Stphane Vie Guerrier is a senior internal medicine resident at the University of Pennsylvania. She graduated from the Perelman School of Medicine in 2019. After she completes her residency in June of 2022, she will join Penns department of endocrinology as a fellow. She enjoys working alongside Penns hardworking and inquisitive medical students, who teach her unexpected lessons every day.

The Michael P. Nusbaum Graduate Student Mentoring Award was established in 2017 to honor Mikey Nusbaum as he stepped down from his role as Associate Dean for Graduate Education and director of Biomedical Graduate Studies.

Christopher Hunter is the Mindy Halikman Heyer Distinguished Professor of Pathobiology in Penns School of Veterinary Medicine. Dr. Hunter has been a mentor far beyond the borders of his own laboratory, through the T32 grant he leads, the courses he directs, and the regular connection with students across several graduate groups. Dr. Hunters thoughtful advice has guided several generations of biomedical graduate studies (BGS) students through their PhD education and beyond. His dedication to mentoring students and guiding them in reaching their scholarly potential exemplifies the type of scientist and mentor that Mikey Nusbaum represents.

The Jane M. Glick Graduate Student Teaching Award was established in 2009 by the Glick family in remembrance of Jane Glick and her dedication to the Biomedical Graduate Studies (BGS) programs.

Dan Beiting is an assistant professor of pathobiology in Penns School of Veterinary Medicine. Dr. Beitings creation of a new teaching model within Biomedical Graduate Studies through the development of the CAMB 714 DIY Transcriptomics course and his innovative approach to deliver biostatistics training with the BIOM 610 course will have a lasting impact on quantitative training for BGS students for years to come. His dedication to these efforts exemplifies the type of scientist/educator that Jane represented.

See the rest here:
Perelman School of Medicine 2022 Teaching Awards | University of Pennsylvania Almanac - Almanac

The Major Findings of Harvards Report on Its Ties to Slavery – The New York Times

In 2019, Harvards president, Lawrence S. Bacow, appointed a committee of faculty members to investigate the universitys ties to slavery, as well as its legacy. Discussions about race were intensifying across the country. Students were demanding that the names of people involved in the slave trade be removed from buildings. Other universities, notably Brown, had already conducted similar excavations of their past.

The resulting 134-page report plus two appendices was released Tuesday, along with a promise of $100 million, to create an endowed fund to redress past wrongs, one of the biggest funds of its kind.

Here are some of its key findings and excerpts.

The report found that enslaved people lived on the Cambridge, Mass., campus, in the presidents residence, and were part of the fabric, albeit almost invisible, of daily life.

Over nearly 150 years, from the universitys founding in 1636 until the Massachusetts Supreme Judicial Court found slavery unlawful in 1783, Harvard presidents and other leaders, as well as its faculty and staff, enslaved more than 70 individuals, some of whom labored on campus, the report said. Enslaved men and women served Harvard presidents and professors and fed and cared for Harvard students.

The committee found at least 41 prominent people associated with Harvard who enslaved people. They included four Harvard presidents, such as Increase Mather, president of the university from 1692 to 1701, and Benjamin Wadsworth, president from 1725 to 1737; three governors, John Winthrop, Joseph Dudley and John Leverett; William Brattle, minister of First Church, Cambridge; Edward Wigglesworth, professor of divinity; John Winthrop, professor of mathematics and natural philosophy; Edward Hopkins, founder of the Hopkins Foundation; and Isaac Royall Jr., who funded the first professorship of law at Harvard.

While New Englands image has been linked in popular culture to abolitionism, the report said, wealthy plantation owners and Harvard were mutually dependent for their wealth.

Throughout this period and well into the 19th century, the university and its donors benefited from extensive financial ties to slavery, the report said. These profitable financial relationships included, most notably, the beneficence of donors who accumulated their wealth through slave trading; from the labor of enslaved people on plantations in the Caribbean islands and in the American South; and from the Northern textile manufacturing industry, supplied with cotton grown by enslaved people held in bondage. The university also profited from its own financial investments, which included loans to Caribbean sugar planters, rum distillers, and plantation suppliers along with investments in cotton manufacturing.

Early attempts at integration met with stiff resistance from Harvard leaders who prized being a school for a white upper crust, including wealthy white sons of the South.

In the years before the Civil War, the color line held at Harvard despite a false start toward Black access, the report said. In 1850, Harvards medical school admitted three Black students but, after a group of white students and alumni objected, the schools dean, Oliver Wendell Holmes Sr., expelled them.

Harvard faculty members played a role in disseminating bogus theories of racial differences that were used to justify racial segregation and to underpin Nazi Germanys extermination of undesirable populations.

In the 19th century, Harvard had begun to amass human anatomical specimens, including the bodies of enslaved people, that would, in the hands of the universitys prominent scientific authorities, become central to the promotion of so-called race science at Harvard and other American institutions, the report said.

The bitter fruit of those race scientists remains part of Harvards living legacy today.

One of those race scientists was the naturalist and Harvard professor Louis Agassiz, who commissioned daguerreotype portraits of enslaved people Delia, Jack, Renty, Drana, Jem, Alfred, and Fassen in an attempt to prove their inferiority. The report does not mention that Tamara Lanier, a woman who has traced her ancestry to Renty, had challenged Harvards ownership of the portraits, saying that the images of Renty and his daughter Delia, taken under duress, are the spoils of theft.

Until as recently as the 1960s, the legacy of slavery lived on in the paucity of Black students admitted to Harvard.

During the five decades between 1890 and 1940, approximately 160 Blacks attended Harvard College, or an average of about three per year, 30 per decade, the report said. In 1960, some nine Black men numbered among the 1,212 freshman matriculants to Harvard College, and that figure represented a vast improvement over the prior decades.

See the original post:
The Major Findings of Harvards Report on Its Ties to Slavery - The New York Times

Carolyn Meltzer bringing integrity, a collaborative spirit, and a sense of service to taking on the toughest health challenges | Keck School of…

The new Dean sees Keck School of Medicine of USC as uniquely positioned to lead the health care innovation of tomorrow with its academic excellence and diverse urban community.

By Laura LeBlanc

Coming up through the ranks in medicine over the last three decades, Carolyn Meltzer has been part of great change, both in her areas of specialty, neuroradiology and nuclear medicine, and in the culture of medicine itself. As the new Dean of the Keck School of Medicine of USC, she sees the opportunity for the school to play a leading role in driving the innovations needed in health care now to take on the toughest diseases and make the system equitable and accessible.

Prior to joining USC, she was at Emory University School of Medicine, serving as Chair of the Department of Radiology and Imaging Sciences, the Executive Associate Dean for Faculty Academic Advancement, Leadership and Inclusion, and the William P. Timmie Endowed Professor. We sat down with her to talk about where shes been and where see sees the Keck School going.

When did you realize you wanted to go into medicine?

I was good at math and science and from high school on I was always intrigued with the brain how it works, the connections between biology, neurobiology and our cognitive selves. So, I thought I would become a scientist. My dad, a Greek immigrant, would always say consider medicine. I had worked in many laboratories and knew I was excited about research. But I thought, What if I turn out to be a terrible doctor? Still, secretly I let myself think about it. In college I got involved in a group called Women in Medicine where I was exposed to speakers who were physicians and women role models and decided that was the way to go.

What drew you to neuroradiology, medical imaging focusing on abnormalities of the brain, spine, head, and neck?

When I did my clinical rotation in neurology at medical school, I was with a chief resident at the county hospital and all he wanted to do was go look at the imaging. He kept saying, There are so many cool things. And really, we cant diagnose a lot without the imaging. Then I did some research in neuroimaging, in PET imaging, and thought, This is what I want to do. The problem solving, the spatial piece, the technology neuroradiology combines all of it. I love technology and being challenged with things innovating constantly.

Youve mentored more than 70 undergraduate and graduate students. Why is mentoring important to you and what do you gain from it?

I was a first-generation college and medical student. I had no idea what I was doing. I had people who spent time with me, supported me, who taught me things that other students were much more prepared for. And thats had such an impact on my life as well as my career. For me, its about giving back. But I also feel I continuously learn from my mentees, the questions they ask, which helps me evolve in how I approach them.

How has your experience coming up through the ranks in the medical field informed your approach to creating a culture of diversity, inclusion and equity?

When I went to medical school, only about a third of my class were women. And there was this deeply embedded culture, of very traditional, systemic, second-generation gender bias. Not to say we didnt have a lot of really supportive people. But basically, there was a masculinity in all of the terminology, how strong you could be, how tough you could be. As I got more comfortable with who I was in medicine and what I was pursuing, I was more able to be my authentic self. And thats really important. I think with folks who are identified with groups that are historically underrepresented in medicine, theres this sense of code switching where you have to be a certain self at work and then you can be more comfortable at home. Considering that is this an institution where people feel like they can be their authentic selves, where they feel like they belong is part of the inclusion piece, of creating an inclusive climate.

What three words best describe your leadership style?

Collaborative Im not afraid to make decisions, but I really want a lot of input. I know Ill make better decisions if I have a diverse team of people who bring different experiences and feel comfortable speaking up. Integrity values-based leadership is really important to me. As a leader you need to know where your own red line is, your own sense of whats right and wrong, to ensure the decisions you make are true to it. Finally theres a servant aspect. Servant leadership means when you agree to lead, you agree to serve others.

What excites you most about your new role as dean here?

The opportunity for positive impact. The people here are incredible. Together with the investments and the strategic focus that President Folt has set forward with Steve Shapiro, theres an extraordinary opportunity for us, uniquely as an institution, to address some complex problems in health care. Our connection with the community in one of the most diverse urban areas in the world allows us to work with those we serve to find solutions to the tough problems improving treatments for complex disease, mitigating the effects of climate change,

Imaging is not only your vocation its also your art and your work has been featured in about 60 exhibitions in the US and Europe. Has it influenced the way you approach medicine or research?

Obviously, its related in terms of the medium, but I think its more about spending time doing something separate from medicine. Also feeling comfortable showing my work and saying, Yes, Im a physician. Yes, Im a photographer. I dont have to be one or the other. Ill tell you a funny story I was once on a flight to a medical meeting in Beijing and I had brought my tripod, all my equipment. The flight attendant helped me put my tripod in the bin and he said, Oh, are you a photographer? I said, Yes. And we chatted a little bit about photography. Then somebody got sick on the plane, and they called for a doctor, and I got up and he said, I thought you were a photographer.

Tell us about your family. I understand youre a dog person and that one of them can read!

My husband and I have four rescue dogs. Weve been doing rescue work for a long time. Neither of us has the ability to say no to the other when one wants to bring an animal home. Ive had two therapy dogs and worked with them in all kinds of settings a school for the blind, childrens hospitals, nursing homes. Library programs have been particularly rewarding. Its easier for a child to feel comfortable reading to a furry cuddly dog than to an adult who may be correcting them. So, I always say, My dog can read, so do you want to read with him? And theyll read together. But COVID made my therapy dog fat and lazy. He couldnt go into libraries for two years. Now he just wants to lie on the couch.

Follow Dean Meltzer on Twitter@DeanMeltzerand Instagramdeanmeltzer_keckschool.

Read the original here:
Carolyn Meltzer bringing integrity, a collaborative spirit, and a sense of service to taking on the toughest health challenges | Keck School of...

Hormones may explain link between excess weight and endometrial cancer – Medical News Today

Endometrial cancer is the most common cancer affecting the female reproductive tract in high-income countries. In the U.K., one in 36 women are estimated to be diagnosed with endometrial cancer in their lifetime.

Research has indicated that women with a high BMI are more at risk of developing endometrial cancer.

BMI is calculated using a persons height and weight and is used to determine if a persons weight is within a healthy range. A BMI score of 20-25 is considered healthy, a BMI over 25 is considered overweight, over 30 is considered obese, and over 40 is considered severely obese, as accepted by the NHS. BMI is an indirect measure of fat tissue and it is less accurate in some individuals, hence remains controversial.

Dr. Sarah Gray, a general practioner who specializes in womens health, told Medical News Today in an interview that 20 years ago she worked on developing guidelines at The National Institute for Health and Care Excellence (NICE) for women with heavy periods, which can be a symptom of endometrial cancer. The guidelines concluded that the chance of getting uterine cancer below the age of 45, was really very remote.

She explained that as rates of obesity had increased in the population, this had changed:

Ive got a colleague who is now occasionally seeing uterine cancer in women in their early 30s, she said.

Now, a study published in BMC Medicine has quantified the increase in the risk of endometrial cancer in women with a high BMI and has proposed a mechanism for the link.

A team led by researchers from the University of Bristol, with support from Cancer Research U.K., carried out an analysis of genetic samples and health information taken from the Endometrial Cancer Association Consortium, the Epidemiology of Endometrial Cancer Consortium, and the U.K. Biobank.

Of the 121,885 women largely of European descent (from Australia, Belgium, Germany, Poland, Sweden, the U.K., and the U.S.) included in this study, 12,906 of these women had endometrial cancer.

They found an increase of 5 BMI points was associated with an 88% increase in risk of developing endometrial cancer.

They also discovered that increased testosterone, increased fasting insulin, and decreased sex hormone-binding globulin were associated with an increase in the risk of developing endometrial cancer.

Further analysis by the researchers also found evidence that BMI had an effect on fasting insulin, sex hormone-binding globulin, bioavailable testosterone, and the inflammatory marker C-reactive protein.

The authors hypothesize that increased BMI indicated increased fat tissue, which leads to increased fasting insulin and reduced sex hormone-binding globulin. This, in turn, leads to increased bioavailable testosterone. This testosterone can then be converted into estrogen, which may also increase the risk of endometrial cancer.

Dr. Alpa Patel, senior vice president of population science at the American Cancer Society, explained the link between BMI and endometrial cancer risk wasnt necessarily a new one.

We do know that especially in visceral fat that surrounds an organ, [which] is quite metabolically active, [that] is what increases your risk of both insulin resistance and hyperinsulinemia or higher levels of insulin, which can affect endometrial cancer risk, she told MNT.

Dr. Patel also touched on how menopause and hormonal changes may affect cancer risk.

After menopause, in fat cells themselves, you have conversions, of androgen (such as testosterone) to estrogen through an enzyme called aromatase. And that [ultimately] increases the conversion to different types of estrogen, and estradiol, which increases your risk of endometrial cancer because it is a hormone-related cancer in women. Dr. Alpa Patel

Dr. Patel said there was a direct link between excess body weight after menopause, owing to the increases in the conversion of androgen to estrogen, which can also increase the risk of endometrial cancer.

So, its not the androgens like testosterone alone. Its the increased conversion of those to estrogen through aromatase after menopause, she added.

Dr. James Yarmolinsky, the lead author of the study from the University of Bristol Medical School, explained to MNT how the study could influence clinical practice.

We try to understand mechanisms. This potentially opens up the possibility of targeting these particular molecules implicated, so mainly insulin and testosterone, he said.

[There are] medications like metformin, for example, which we know can increase insulin signaling. [T]hey help in the management of type 2 diabetes, which, in principle, potentially, could be repurposed in some way for endometrial cancer chemoprevention, he suggested.

Dr. Yarmolinsky said that the findings alone couldnt say whether this was a viable approach but it was a first step in the right direction.

Dr. Gray, meanwhile, said the studys findings could prompt women with a high BMI to be more aware of the symptoms of endometrial cancer, so they seek medical help in a timely manner.

Women who are particularly obese need to be able to monitor their periods. If they go chaotic, erratic, or heavy, then the test is ever so simple. Its going to be an ultrasound and/or a sample taking, she said.

See the article here:
Hormones may explain link between excess weight and endometrial cancer - Medical News Today

Racism in Medicine: But Where Do You Really Come From? – Medscape

Racism in medicine is real, with negative consequences for patients, physicians, and the public as a whole. This point is not in dispute. I have been a victim of racism on multiple occasions. Sometimes an interaction is so traumatic that I try to forget, to bury it and move on. The feeling that you're a second-class citizen makes it that much more difficult to carry out the day-to-day work of medicine.

Given the problem and prevalence of racism in medicine, it's time for a real overhaul one backed by concrete steps rather than symbolic ones. It doesn't matter if you change the name of a building or a street; what matters is the actionable steps taken to ensure that people are treated fairly.

That said, I wonder if we sometimes overreact to certain remarks because we assume, based on (traumatic) prior experiences, that they are coming from a bad place. I say this not to discount or diminish the very real racial discrimination suffered by myself and my colleagues every day. However, I've found that it's also possible to misinterpret certain questions or statements when we don't have more context.

I say this from my own personal experience. Let me share two examples.

This past December, a 74-year-old woman with colorectal cancer was waiting for me in the clinic. She has been on first-line chemotherapy of FOLFIRI for several months, but I was seeing her for the first time.

After I walk into the exam room, we chat a little to build rapport. Naturally, the discussion is about Canadian winter and Christmas.

Suddenly, she asks a question that takes me by surprise: "Are you allowed to celebrate Christmas?"

I am startled because the conversation so far has been pleasant. I reply rather tersely, "Apparently, it's not yet illegal in Canada for everyone to celebrate Christmas."

She doesn't pursue it further. We talk about blood work, toxicities, scans, the usual. Thankfully, there was no bad news before Christmas.

As I am about to wrap up our encounter, she launches into the topic again, saying, "My daughter-in-law never celebrated Christmas. She was a Hindu from India."

I stop. I am still a bit offended that she assumed I was from India (I am not), and that even if I were, she assumed I'd be a Hindu by default (though I am).

But at this point I'm also intrigued. I ask, "Was? You said your daughter-in-law 'was.' What happened?"

With tears in her eyes, she says, "She passed away young. She was nice. But she didn't know anything about Christmas and never celebrated one. I thought that was because of her religion."

I thought about this encounter for several hours after. I'd been offended by her suppositions and generalizations, but once home, I recalled that as children in Nepal, we referred to every White person as American, and every East Asian as Japanese. We were and still are surprised and amused when non-Hindus celebrate our festivals like Dashain and Holi alongside us in Nepal.

Now an argument can be made that this is merely lack of education, and that everyone, with the means, should educate themselves that such generalizations can be dangerous and hurtful. But in this case, I could see that the question had come from a place of genuine inquiry with the emotional overlay of her past experience. There was no intended slight against me.

On another day in December, I meet a 78-year-old man with metastatic prostate cancer, accompanied by his wife. The news isn't good. The scans show disease progression.

I am seeing them for the first time, and when I enter the exam room, I greet them. After some basic introduction, they ask me, "Where are you from?"

I immediately take offense at this classic line of racial stereotyping.

My response: "From Canada," hoping the two words would dead-end the conversation.

But they probe further.

"Now, where are you really from?" Again I answer "From Canada," wishing in this moment that masks and face shields could hide my identity.

And again: "No, where did you actually come from? Where were you born?"

By now I am irritated. I lie, saying, "In Canada. I was born in Canada." Not because I am not proud of my heritage (I am super-proud), but I have learned that people often ask these questions to racially profile, discriminate, and undermine.

At last, we turn to medical matters. I break the bad news, albeit not as well as I had hoped. To my surprise, they take it calmly.

The couple then asks about my holiday plans and mentions that one of their kids is coming back home and they are really excited.

And suddenly, they blurt out, "You know what, doc, we came here from the Czech Republic several years ago, and it has not been easy for us learning a new language and raising kids. This young son, he is now in medical school and will soon become a doctor. We are so proud of him. For immigrants like us, it really means a lot. This country has given us so much and we feel very grateful."

Wow. I realized that I had completely misunderstood them. They were asking about my roots because they saw their own son in me, as an immigrant. I had thought they must be Canadians because they looked White. The mistake wasn't theirs it was mine!

Finally, I told them that I was from Nepal. They were immediately interested, looking up Nepal in Google Maps. We embarked on a long discussion about different cultures. Toward the end of our conversation, they said they'd really like their son to grow up to be a doctor like me.

The biggest compliment came next: They asked if I could be their oncologist moving forward.

I'm relaying these encounters with patients not to generalize that all "Where are you from?" comments are innocuous. I have been on the receiving end of similar remarks from patients that were intended as microaggressions, or sometimes overt discrimination.

These interactions also made me recall that before I moved to North America, I always assumed that this kind of question came from a place of interest, and I took it as an opportunity to talk about my country and my culture. Only after moving to North America did I learn that these questions are not necessarily genuine or harmless.

However, after these two encounters with patients, I began to wonder whether I had transitioned from being unaware or less aware of the racial implications of certain questions to being overly sensitive. I also wondered whether I could channel this emotional energy into positive change.

And there's a lot of work to do. We need to address systemic racism in access to cancer care, cancer outcomes, healthcare workers' education, and career opportunities. We need to address deep-seated biases about people's appearances, ethnicity, and culture.

When racial minorities ask for equality, they are asking for equal access to education, treatment, career opportunities, and salary, as well as to justice, respect, and freedom. A world that doesn't address these issues but simply stops asking us where we come from is not the just world we are seeking.

Addressing these issues would go a long way toward creating a more level playing field, toward real equality. In such a world, being asked "Where do you come from?" would not feel so loaded with judgment about who I am. In that world, I might once again feel confident that this question comes from a genuine place of interest.

Bishal Gyawali, MD, PhD, is an associate professor in the Departments of Oncology and Public Health Sciences and a scientist in the Division of Cancer Care and Epidemiology at Queen's University in Kingston, Ontario, Canada, and is also affiliated faculty at the Program on Regulation, Therapeutics, and Law in the Department of Medicine at Brigham and Women's Hospital in Boston. His clinical and research interests revolve around cancer policy, global oncology, evidence-based oncology, financial toxicities of cancer treatment, clinical trial methods, and supportive care. He tweets at@oncology_bg.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Read more:
Racism in Medicine: But Where Do You Really Come From? - Medscape

UAMS to Offer Mindfulness-Based Stress Reduction Program – UAMS News

View Larger Image UAMS is offering a Mindfulness-Based Stress Reduction (MBSR) Program online starting March 2.

Jan. 28, 2022 | LITTLE ROCK The University of Arkansas for Medical Sciences (UAMS) Mindfulness Program is offering the Mindfulness-Based Stress Reduction (MBSR) Program online starting March 2.

Participants learn mindfulness techniques that foster positivity, inner strength and peace, while providing useful skills for navigating difficulty, stress, illness and pain.

The program is an eight-week, nine-session training in mindful awareness and meditation skills. Classes meet weekly online for about two hours and for an all-day session toward the end of the course.

Orientation is 5:30-7 p.m. Wednesday, March 2. Classes one through eight meet from 5:30 p.m. to 8 p.m. Wednesdays, March 9 to April 27. The all-day class and retreat is 9 a.m. to 3 p.m. Saturday, April 16.

The cost for the course is $300 and covers materials. UAMS employees may take the course for $250. Couples or families can receive a group rate of $225 per person. Scholarships are also available.

To register or apply for a scholarship, visit Mindfulness.UAMS.edu. For questions, contact UAMSMindfulnessProgram@uams.edu.

MBSR was developed by Jon Kabat-Zinn, Ph.D., in 1979 at the University of Massachusetts Medical School and is a form of mindfulness and meditation that is well-documented and supported by scientific studies. Participants learn different meditative tools to mindfully explore healthier relationships with the day-to-day challenges and demands of life.

Elements include:

The course is taught by Feliciano Pele Yu Jr., M.D., a professor of pediatrics, biomedical informatics and public health at UAMS; associate director of the UAMS Mindfulness Program; and certified Koru Mindfulness teacher who has completed the MBSR Teacher Training Intensive through the University of California San Diego Mindfulness-Based Professional Training Institute.

Professor of Psychiatry Puru Thapa, M.D., is director of the UAMS Mindfulness Program, which offers Mindfulness teachings and courses to the UAMS community and the general public. For more information, visit Mindfulness.UAMS.edu.

###

Read the original post:
UAMS to Offer Mindfulness-Based Stress Reduction Program - UAMS News

Interim Leadership Named at Dell Medical School – UT News – UT News – UT News | The University of Texas at Austin

The following is a letter from Jay Hartzell, president of The University of Texas at Austin, sent to campus on July 15, 2021.

Dear UT Community,

Last week, we announced that Clay Johnston was stepping down from his roles as Dean of the Dell Medical School and Vice President for Medical Affairs at UT. We are incredibly grateful to Clay for his stellar leadership and glad that his pursuit of exciting new opportunities will still permit him to play a key role on our transition team and to continue helping our transformation effort as we push the boundaries of how we think about health not just health care at Dell Med.

This transition also presents an opportunity for UT to consider how we build our leadership structure to support the next chapter of expansion, growth and excellence in our medical journey. After consulting with Clay, our leadership team, and other stakeholders at the medical school, we have decided to take the opportunity of this transition to separate the two roles of Dell Med Dean and UT Vice President for Medical Affairs.

The monumental growth at Dell Med during the past seven years makes this structural change both necessary and exciting. The school will continue to be one of the most innovative and transformative medical schools in America, attracting incredible students and faculty members who are drawn to its unique position. Similarly, UT Health Austin, our clinical practice,which has grown fivefold since 2018,will continue to provide increasing amounts of world-class care to our community.This change is also a testament to our deep commitment to investing in outstanding staff members who play a powerful role in our universitys mission.

To enable us to continue to grow and develop while we have some uncertainty about the timing of Clays next role, weve asked George Macones, M.D., chair of Dell Meds Department of Womens Health, to serve as interim Dean, beginning September 1. Also, Martin Harris, M.D., MBA, the schools Associate Vice President of the Health Enterprise and Chief Business Officer, has agreed to be our interim Vice President for Medical Affairs, beginning August 1.

Moving forward, well follow standard UT procedures for selecting a new dean, a process that begins with an election of faculty members to form the basis for a search committee that advises university leadership along the way. Well also begin the search for a Vice President for Medical Affairs by convening a second search committee that will be chaired by Professor Chuck Fraser, M.D., Dell Meds chief of the Division of Cardiothoracic Surgery, and Amy Shaw Thomas, Senior Vice Chancellor for Health Affairs with The University of Texas System.

Thanks to the work of Clay and countless others, our medical school is on an exciting trajectory. We look forward to engaging with the campus community during the coming months as we work together to write the next chapters of Dell Meds powerful and transformative story as a place that changes the impact and reputation of UT Austin and health in Austin, Texas, and ultimately, the world.

Sincerely,

Jay HartzellPresident

Sharon WoodExecutive VP and Provost Designate

Continued here:
Interim Leadership Named at Dell Medical School - UT News - UT News - UT News | The University of Texas at Austin

Unraveling the Mystery of Touch | Harvard Medical School – Harvard Medical School

Some parts of the bodyour hands and lips, for exampleare more sensitive than others, making them essential tools in our ability to discern the most intricate details of the world around us.

This ability is key to our survival, enabling us to safely navigate our surroundings and quickly understand and respond to new situations.

Get more HMS news here

It is perhaps unsurprising that the brain devotes considerable space to these sensitive skin surfaces that are specialized for fine, discriminative touch and which are continually gathering detailed information via the sensory neurons that innervate them.

But how does the connection between sensory neurons and the brain result in such exquisitely sensitive skin?

A new study led by researchers at Harvard Medical School has unveiled a mechanism that may underlie the greater sensitivity of certain skin regions. The research, conducted in mice and published Oct. 11 in Cell, shows that the overrepresentation of sensitive skin surfaces in the brain develops in early adolescence and can be pinpointed to the brain stem.

Moreover, the sensory neurons that populate the more sensitive parts of the skin and relay information to the brain stem form more connections and stronger ones than neurons in less sensitive parts of the body.

This study provides a mechanistic understanding of why more brain real estate is devoted to surfaces of the skin with high touch acuity, said senior author David Ginty, the Edward R. and Anne G. Lefler Professor of Neurobiology at Harvard Medical School. Basically, it's a mechanism that helps explain why one has greater sensory acuity in the parts of the body that require it.

While the study was done in mice, the overrepresentation of sensitive skin regions in the brain is seen across mammalssuggesting that the mechanism may be generalizable to other species.

From an evolutionary perspective, mammals have dramatically varied body forms, which translates into sensitivity in different skin surfaces. For example, humans have highly sensitive hands and lips, while pigs explore the world using highly sensitive snouts. Thus, Ginty said this mechanism could provide the developmental flexibility for different species to develop sensitivity in different areas.

Moreover, the findings, while fundamental, could someday help illuminate the touch abnormalities seen in certain neurodevelopmental disorders in humans.

Scientists have long known that certain body parts are overrepresented in the brainas depicted by the brains sensory map, called the somatosensory homunculus, a schematic of human body parts and the corresponding areas in the brain where signals from these body parts are processed. The striking illustration includes cartoonishly oversized hands and lips.

Previously, it was thought that the overrepresentation of sensitive skin regions in the brain could be attributed to a higher density of neurons innervating those skin areas. However, earlier work by the Ginty lab revealed that while sensitive skin does contain more neurons, these extra neurons are not sufficient to account for the additional brain space.

We noticed that there was a rather meager number of neurons that were innervating the sensitive skin compared to what wed expect, said co-first author Brendan Lehnert, a research fellow in neurobiology, who led the study with Celine Santiago, also a research fellow in the Ginty lab.

It just wasnt adding up, Ginty added.

To investigate this contradiction, the researchers conducted a series of experiments in mice that involved imaging the brain and neurons as neurons were stimulated in different ways.

First, they examined how different skin regions were represented in the brain throughout development. Early in development, the sensitive, hairless skin on a mouses paw was represented in proportion to the density of sensory neurons.

However, between adolescence and adulthood, this sensitive skin became increasingly overrepresented in the brain, even though the density of neurons remained stablea shift that was not seen in less sensitive, hairy paw skin.

This immediately told us that theres something more going on than just the density of innervation of nerve cells in the skin to account for this overrepresentation in the brain, Ginty said.

It was really unexpected to see changes over these postnatal developmental timepoints, Lehnert added. This might be just one of many changes over postnatal development that are important for allowing us to represent the tactile world around us, and helping us gain the ability to manipulate objects in the world through the sensory motor loop that touch is such a special part of.

Next, the team determined that the brain stemthe region at the base of the brain that relays information from sensory neurons to more sophisticated, higher-order brain regionsis the location where the enlarged representation of sensitive skin surfaces occurs.

This finding led the researchers to a realization: The overrepresentation of sensitive skin must emerge from the connections between sensory neurons and brain stem neurons.

To probe even further, the scientists compared the connections between sensory neurons and brain stem neurons for different types of paw skin. They found that these connections between neurons were stronger and more numerous for sensitive, hairless skin than for less sensitive, hairy skin. Thus, the team concluded, the strength and number of connections between neurons play a key role in driving overrepresentation of sensitive skin in the brain.

Finally, even when sensory neurons in sensitive skin werent stimulated, mice still developed expanded representation in the brainsuggesting that skin type, rather than stimulation by touch over time, causes these brain changes.

We think we've uncovered a component of this magnification that accounts for the disproportionate central representation of sensory space. Ginty said. This is a new way of thinking about how this magnification comes about.

Next, the researchers want to investigate how different skin regions tell the neurons that innervate them to take on different properties, such as forming more and stronger connections when they innervate sensitive skin.

What are the signals? Ginty asked. Thats a big, big mechanistic question.

And while Lehnert described the study as purely curiosity-driven, he noted that there is a prevalent class of neurodevelopmental disorders in humans called developmental coordination disorders that affect the connection between touch receptors and the brainand thus might benefit from elucidating further the interplay between the two.

This is one of what I hope will be many studies that explore on a mechanistic level changes in how the body is represented over development, Lehnert said. Celine and I both think this might lead, at some point in the future, to a better understanding of certain neurodevelopmental disorders.

Co-investigators included Erica Huey, Alan Emanuel, Sophia Renauld, Nusrat Africawala, Ilayda Alkislar, Yang Zheng, Ling Bai, Charalampia Koutsioumpa, Jennifer Hong, Alexandra Magee, and Christopher Harvey of Harvard Medical School.

The research was supported by the National Institutes of Health (F32 NS095631-01, F32-NS106807, K99 NS119739, DP1 MH125776, R01 NS089521, and R01 NS97344), a William Randolph Hearst Fellowship, a Goldenson Fellowship, a Harvard Medical School Deans Innovation Grant in the Basic and Social Sciences, and the Edward R. and Anne G. Lefler Center for the Study of Neurodegenerative Disorders.

Read more from the original source:
Unraveling the Mystery of Touch | Harvard Medical School - Harvard Medical School

Serving those who served – Northwestern Now – Northwestern University NewsCenter

Russell, you completed a large chunk of your clinical training at Jesse Brown. How did that come to be?

After I had my first medical school rotation at the VA, I chose the VA for every other rotation I could. All of my interactions there were just so positive. I looked forward to coming back during my residency in ophthalmology.

What about the experience drew and kept you there?

The vets are just incredible and they all have such amazing stories. They've all lived through so much. It's people coming from different walks of life, and being there is a very enriching experience. You really feel like you're helping people who have, first of all, served and given so much to everybody in the United States, and also people who really need your help.

Russell Huang

What kind of population do you work with?

Jesse Brown is definitely an inner-city VA. The pathology is very advanced for a lot of these guys. These are people who are struggling with PTSD and other issues. They haven't been able to take care of themselves for years. So, you know, honestly there's nothing better than really just connecting with one of these vets. And, especially as a medical student, you have the ability to do so much. Every little thing that you do for them is so meaningful to them, and it really empowers you as a medical student.

How is the VA experience part of your residency program?

As ophthalmology residents at the VA, we spend at least six months there. Were in the clinic two to three days a week. And by our fourth year, we're in the operating room half the time.

What types of procedures are you doing?

There's a very high incidence of glaucoma and also very advanced cases of cataracts. Many patients walk into our office legally blind from their cataracts. Doing cataract surgery on them is one of the most satisfying surgeries that we do because we can restore their vision.

You must hear interesting stories.

Before COVID, we used to have this big waiting room full of guys, and you could hear them trading war stories, talking to each other about their eyes, talking to each other about everything else that's going on, and cracking jokes. I treated one guy who was working on a screenplay. Its fun.

How is your clinical training different because it is at the VA?

You learn to be very independent very hands-on. The VA really pushes you. You're the doctor, and the buck stops with you. If you think there's something a patient needs, you have to get it done and, for better or worse, thats what makes the VA such a special place.

Continue reading here:
Serving those who served - Northwestern Now - Northwestern University NewsCenter

This Medical School Has An Admission Rate Of Less Than 1%: Heres How To Get In – Forbes

Kaiser Permanente Bernard J. Tyson School of Medicine is one of the newer medical schools it matriculated its inaugural class of 50 students in 2020but it is already one of the most competitive programs in the United States. With nearly 10,500 applicants in 2020-21, the medical school acceptance rate hovers around 0.05%.

Medical school student preparing her applications

Moon Prep sat down with Dr. Lindia J. Willies-Jacobo, MD, the Senior Associate Dean for Admissions. This interview reveals what the new medical school is prioritizing in their applicants and how students can be competitive applicants with resumes full of meaningful experiences, even during a pandemic. The full interview can be viewed here.

Dr. Lindia Willies-Jacobo is the Senior Associate Dean for Admissions and Equity, Inclusion, and ... [+] Diversity; Professor at Kaiser Permanente Bernard J. Tyson School of Medicine

Kristen Moon: What are the advantages and disadvantages of attending a newer medical school like Kaiser Permanente Bernard J. Tyson School of Medicine?

Dr. Lindia J. Willies-Jacobo: It's something we talk with students about during recruitment. Students are extraordinarily risk-averse, making it more difficult to commit to a brand new med school. However, I would argue that being part of a new school allows students to be innovative at our school.

For example, one of the things we've said to our students is they get to provide us with a lot of feedback. As the inaugural class, they have a significant impact on the direction in which the school goes. It tends to be the class that leaves a legacy.

The other piece I point out to students is that when you are building something new, you can think out of the box. I think when one goes to a traditional school that's been around for 10 or 50 years, it's a lot harder to enact even simple changes. With a new medical school, I think of it as a blank canvas that students really get to paint on.

Moon: What was the motivation for offering free tuition for the first five enrolling classes?

Willies-Jacobo: At our school, we do have free tuition and fees for any student who enrolls with us from between 2020-24. Many new schools do something similar and have built into that some level of tuition remission.

When you look at the cost of medical school education, it's astronomical. By offering free tuition, it allows students from economically disadvantaged backgrounds the opportunity to consider coming to medical school.

It also allows the students the opportunities to select specialties that really align with their personal and professional values without thinking too much about how much they're going to be remunerated as physicians later on. The reality is there are loans to be paid off. Students who may want to pursue primary care may decide otherwise because then the remuneration for someone who does primary care is often quite a bit less than someone who does a surgical specialty or another specialty. This frees students up to make specialty decisions beyond thinking about loan payments.

Moon: In 2020-21, the medical school received more than 10,000 applicants, with an acceptance rate of 0.05%. What did you prioritize in your evaluation?

Willies-Jacobo: It's important to know and understand the mission of the school to which you're applying. When mentoring students or talking to pre-med students, I emphasize putting together a portfolio that demonstrates mission alignment.

I've had people say, Well, every application must look exactly the same, but it doesnt. We utilize a holistic approach, and what we are always looking at is whether the student's personal narrative coupled with the experiences they've listed on their application and supportive letters of recommendation fit together in ways that show us that they are mission-aligned.

We designed our secondary or school-specific application and interview process in a way that allows students to demonstrate if their professional and personal goals are aligned with those of the school.

Moon: Another interesting statistic is that 30% or more of your students are non-science majors. How can these non-science majors stand out?

Willies-Jacobo: Unlike when I went to med school when it seemed like everyone was a science major, we now know that depending on the school, you can have upward of 30-40% of non-science majors in your applicant pool. Each year, we see more and more of these types of students applying for medical school.

When we are assessing applicants for readiness for medical school, there are still prerequisites and recommended courses that every student has to take. We want to ensure that students who are non-same majors can also demonstrate readiness from a science perspective. Many non-science students are still academically strong, but they also bring so much value to the institution. Many non-science majors often see things very holistically and with an entirely different set of lenses.

Moon: Can you tell me about your interview process?

Willies-Jacobo: We use the hybrid model because we know that some students tend to thrive in one-on-one interviews, and others may do better in the Multiple Mini Interview (MMI). The hybrid method allows us to attract a diverse pool of students.

This past cycle, we did something very similar but pivoted to a virtual platform. To do so, we cut back on the number of MMI stations because we knew that Zoom fatigue is real. With the hybrid approach, we often will compare how they performed in the MMI versus the traditional interview.

We do find that extroverted students tend to do a lot better in MMI stations. You have to be a self-starter in terms of conversation, and we find that more extroverted students tend to warm up more quickly than introverted students who require a little bit more time.

Moon: How would you recommend students prepare for the hybrid interview?

Willies-Jacobo: Im a huge believer in practice. Of course, some people suggest that you cant practice, but I disagree with that.

I typically encourage students to meet with a mentor and review practice MMI stations or questions to have them practice responding to them. In a virtual space, it is a little harder to answer interview questions because youre not getting as many cues as you would in person.

I remind students that anything that they put in their application is fair game, so remember what you listed. For example, review your research experience, community-based experiences, extracurriculars because inevitably it's going to come on their interviews. There's nothing worse than applying in June, getting interviewed in November and having not a clue what you wrote down.

Moon: How many students do you interview each year and accept?

Willies-Jacobo: We interviewed a little over 700 candidates for about 50 spots. Typically it ends up being about a two-to-one ratio in terms of acceptance versus who ends up matriculating, which is about average for a school of our size.

Moon: How important is it to apply early in the cycle?

Willies-Jacobo: Please apply early. This past year, 60,000 candidates applied to med school, and in any given year, about 60% of students don't get into med school.

If you apply in September or October, it takes four to six weeks for the Association of American Medical Colleges (AAMC) to verify the files. Even though youre a phenomenal candidate, you might not get an interview because school runs out of interview spots.

Moon: How has Covid-19 affected the admission process for students?

Willies-Jacobo: On the national level, there was an 18% increase in applications. Personally, we had an 11% increase in our applications. But another thing that we saw was to make adjustments for the number of experiences that students list on their applications. Students had Fulbright Scholarships canceled. Students had research or volunteer experiences go virtual or canceled altogether. In-person shadowing was also completely off the table.

We did see an increase in students working as Covid-19 contact tracers or virtual medical scribes. Although they couldnt go into hospitals, they still found virtual experiences. We had a lot of students being innovative and really rose to the occasion and made do with what was a very, very challenging admissions cycle.

Moon: What type of services do you provide students to help them succeed?

Willies-Jacobo: Support comes from our Office of Student Affairs. Wellness is a core value, so we have the wellness program coordinator. We also have a clinical psychologist on-site, and one of the things we've tried to do at the school is to normalize mental health. We've encouraged every student to check in with our clinical psychologists at least two to three times in the first year.

We also have pretty robust academic support for the student. We have someone who works with them on study skills and strategies. I also want to highlight our coaching program; every student is paired with a physician coach. Students meet several times a year with their coaching groups. This is a pretty distinctive and forward-thinking aspect of our program.

Students can learn more about Kaiser Permanente Bernard J. Tyson School of Medicine and submit their application through the American Medical College Application System (AMCAS).

More:
This Medical School Has An Admission Rate Of Less Than 1%: Heres How To Get In - Forbes

Dean Jha named one of World’s 50 Greatest Leaders – The Brown Daily Herald

While an undergraduate at Columbia studying economics long before he would be named one of the Worlds 50 Greatest Leaders by Fortune Magazine Ashish Jha, dean of the School of Public Health, was a pre-med student in part because his parents really wanted him to go to medical school. Youre never supposed to tell (that to) anybody in medical school applications, Jha said, laughing.

But despite the initial feeling of obligation to parental expectations, Jha found a deep love for medicine and then public health while getting his MD at Harvard. I feel like its been such a huge part of my identity, Jha said. As a doctor, you get these very concrete skills that you can use to alleviate suffering, to take people who are in pain, to take people who are going through a difficult time and to make that better, he added.

Jha has been a cable news channel mainstay throughout the COVID-19 pandemic, focusing on helping viewers navigate the complex time by providing accessible commentary on the coronavirus and public health measures. He also maintained a popular Twitter account and a steady presence in prominent news media, both as a source and an author. In addition, Jha has been a guest on The Heralds COVID Pod, and published a Jan. 28 op-ed in The Herald.

Jha uses his widespread presence across platforms to broaden his audience. The people you reach through television are different than the people you reach through newspapers (who are) different from people you reach through social media, he said. If you want to communicate to a broad group of people, youve got to use multiple mediums.

Fortune Magazine named him one of the Worlds 50 Greatest Leaders in May for his focus on providing easy-to-understand analysis about the pandemic through multiple mediums with a healthy sprinkling of empathy.

Theres a whole group of people working on this tirelessly, and its really our collective effort that makes a difference, Jha said when asked about the accolade. For Jha, the idea of one person getting the credit for work done by a team of experts has always seemed odd.

One of the things I love about being at Brown is its incredible community of scientists, advocates, and we all work together in what seems like a one-person show, (but) is really an entire team working on all of these issues, he added.

Having come to the University less than a year ago from Harvard, where he was the faculty director of its Global Health Institute, Jha has already begun to build a team around him to drive the COVID-19 response and the work of the Public Health school.

He empowers others, said Stefanie Friedhoff, senior director of content, strategy and public affairs and professor of the practice at the School of Public Health. He has the ability to just bring really diverse voices to the table for a conversation focused on solving problems, she added.

He is a really great leader. He is both visionary, able to articulate where things should go and why, and he is someone who creates space for others to develop their own visions and strategies, Megan Ranney MPH10, professor of emergency medicine and associate dean of strategy and innovation for the School of Public Health, said.

Ranney first met Jha around a year and a half ago, before he had come to Brown and when both were working on providing public health guidance at the start of the pandemic. Soon they were co-writing an article in the New England Journal of Medicine and appearing together on television. (We) struck up a friendship, Ranney said. It was neat to be on (television) with another person who was intelligent and interesting and well spoken.

Now together at the School of Public Health, Ranney has found working alongside Jha a terrific experience. The two of us are strongly aligned in the importance of the research and education and scholarship that we do, she added. I feel very, very lucky to have him here its just such a delight to get to work with him.

Despite Jhas position as a leader in the public health field and his frequent appearances on television, he says he has shared the anxieties felt by many people throughout the pandemic. On a personal level, he said, there has been a lot of uncertainty, concern about making sure that my family is safe my immediate family, of course, my spouse and kids, but also my elderly parents and other friends and family.

But he has been nonetheless driven by a sense that everything he has done in the past year and a half is part of (his) job to communicate to people about what is happening with this disease and the pandemic.

I think theres a recognition that we as a society really are all in this together, Jha said. There is an understanding that everybodys fate is tied to everybody elses, he added. A recognition of our common humanity, not just within our country, but globally.

Link:
Dean Jha named one of World's 50 Greatest Leaders - The Brown Daily Herald

Investigational Alzheimer’s drug improves biomarkers of the disease Washington University School of Medicine in St. Louis – Washington University…

Visit the News Hub

International clinical trial yields mixed results with unclear cognitive effects but promising biomarker results

Randall Bateman, MD, director of the Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), an ongoing international clinical trial to evaluate experimental Alzheimers drugs, speaks with DIAN-TU participant Taylor Hutton. One of the drugs tested in the DIAN-TU, gantenerumab, improved biomarkers of disease despite unclear cognitive effects, prompting study leaders to offer participants the option of continuing to receive the drug and participate in follow-up examinations as part of a so-called open label extension.

An investigational Alzheimers drug reduced molecular markers of disease and curbed neurodegeneration in the brain, without demonstrating evidence of cognitive benefit, in a phase 2/3 clinical trial led by researchers at Washington University School of Medicine in St. Louis through its Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU). These results led the trial leaders to offer the drug, known as gantenerumab, to participants as part of an exploratory open-label extension. The researchers continue to monitor changes in measures of Alzheimers disease in those participants who are receiving the drug.

The DIAN-TU study (ClinicalTrials.gov Identifier: NCT01760005), published June 21 in Nature Medicine, evaluated the effects of two investigational drugs gantenerumab, made by Roche and its U.S. affiliate, Genentech, and solanezumab, made by Eli Lilly and Co. in people with a rare, inherited, early-onset form of Alzheimers known as dominantly inherited Alzheimers disease or autosomal dominant Alzheimers disease. Such people are born with a mutation that causes Alzheimers, and experience declines in memory and thinking skills starting as early as their 30s or 40s.

Gantenerumab had a major impact on Alzheimers biomarkers, said principal investigator Randall J. Bateman, MD, director of DIAN-TU and the Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University. The drugs ability to shift multiple Alzheimers biomarkers toward normal indicates that it is positively affecting the disease process. The effect was strong enough that we launched an open-label extension of the trial so participants have the opportunity to stay on the drug as we continue to study it.

Over the past few decades, scientists have pieced together the changes that occur as Alzheimers develops, a process that takes 20 years or more. First, the protein amyloid beta starts forming plaques in the brain. Later, levels of tau and neurofilament light chain rise in the cerebrospinal fluid that surrounds the brain and spinal cord, and the brain begins to shrink. Then, tangles of tau protein form in the brain. Only then do people with the disease start exhibiting signs of memory loss and confusion.

In this study, 52 patients were randomized to gantenerumab, which led to a reduction in the amount of amyloid plaques in the brain, and lowered soluble tau and phospho-tau, and slowed the rise of neurofilament light chain levels in the cerebrospinal fluid. Neurofilament light chain is a marker that reflects neurodegeneration. Overall, gantenerumabs safety profile in this trial was consistent with that from other clinical trials of the investigational medicine, and no new safety issues were identified.

The primary endpoint of the DIAN-TU study was the prevention or slowing of cognitive decline in people who are nearly certain to develop Alzheimers due to genetic mutations. Neither drug met the primary endpoint, although the study wasnt able to determine effects on thinking and memory in participants who entered the study without symptoms, because they exhibited little to no decline in cognitive function. The study also was unable to assess the effects of higher doses of the drugs, which were escalated to the desired levels late in the trial after a protocol amendment. Participants who received gantenerumab started on a low dose and only started ramping up to a fivefold higher target dose about halfway through the trial, prompted by observations from other studies of gantenerumab.

However, as a secondary endpoint, the study also evaluated the effect of the drugs on molecular and cellular signs of Alzheimers disease. On these measures, gantenerumab showed potential benefit.

These biomarker results suggest that gantenerumab had a favorable impact on the target and downstream markers of Dominantly Inherited Alzheimers Disease, said Rachelle Doody, MD, PhD, global head of neurodegeneration at Roche and Genentech. We support the continued scientific investigation of gantenerumab in Washington Universitys exploratory, open-label extension study to build on learnings from DIAN-TU-001, and are grateful to be a part of this close collaboration between industry, academia and patients as we continue to tackle the complex challenge of Alzheimers disease. We are encouraged by the advancements being made and look forward to continued progress for people with Alzheimers disease.

This trial followed 144 participants for up to seven years; the average follow-up was about five years. All participants carry a genetic mutation that causes a form of Alzheimers dementia at early ages. The researchers recruited participants who were expected to develop symptoms within 15 years or who already had very mild symptoms of memory loss and cognitive decline at the trials outset. In most cases, their brains already showed early signs of disease. Participants were randomly assigned to receive solanezumab, gantenerumab or a placebo.

Although the trial focuses on people with rare mutations, drugs that are successful in this population would be promising candidates for preventing or treating the forms of Alzheimers that occur more commonly in older adults. The destructive molecular and cellular processes in the brain are similar in both types of the disease, Bateman said.

Salloway S, Farlow M, et al. A Trial of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimers Disease. Nature Medicine. June 21, 2021. DOI: 10.1038/s41591-021-01369-8

Data analyzed in this paper was obtained with the support of the National Institute on Aging of the National Institutes of Health (NIH), grant numbers U01AG042791, U01AG042791-S1, R01AG046179, R01AG053267-S1 and U19AG032438; the Alzheimers Association; Eli Lilly and Co.; Roche and Genentech, a member of the Roche group; Avid Radiopharmaceuticals; GHR Foundation; an anonymous organization; Cogstate; Signant; the German Center for Neurodegenerative Diseases; the Raul Carrea Institute for Neurological Research; the Japan Agency for Medical Research and Development; and the Korea Health Industry Development Institute.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, consistently ranking among the top medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Go here to see the original:
Investigational Alzheimer's drug improves biomarkers of the disease Washington University School of Medicine in St. Louis - Washington University...

In Memoriam: Jean Wilson, M.D., made scientific discoveries that led to effective prostate treatments, insights into sexual differentiation – UT…

DALLAS June 21, 2021 Jean D. Wilson, M.D., an internationally known endocrinologist whose scientific discoveries led to profound insights into the mechanisms underlying sexual differentiation and led to now widely used treatments for prostate disease, died June 13. He was 88.

Wilson, seen here in 1962, graduated from UTSouthwestern Medical School in 1955 and joined the faculty in 1960, where he began his studies of testosterone.

Wilson, professor emeritus of internal medicine at UTSouthwestern, was largely responsible for current understanding of the mechanisms by which steroid hormones induce male sexual differentiation. He also was instrumental in identifying the scientific underpinnings of a widely prescribed class of drugs known as 5-alpha-reductase inhibitors which include finasteride (Proscar, Propecia) and dutasteride (Avodart) to treat enlarged prostate and balding in men.

Wilsons discovery of 5-alpha-reductase and the identification of dihydrotestosterone as the primary hormone associated with the growth of the prostate transformed our understanding of prostate gland growth and paved the way for new effective treatment of prostate disease, says Daniel K. Podolsky, M.D., president of UTSouthwestern. His findings led to the first medical therapy for benign prostatic hyperplasia, and also provided the basis for understanding of the mechanism underlying the differentiation of male and female genital development. His legacy will be found in the legions of patients who have benefited from the therapy made possible by his discoveries.

Wilson, seen in 1978, was a popular and highly sought-after attending physician on the wards of Parkland Memorial Hospital, valued for his vast expertise in endocrinology and medicine in general.

Jean Wilson was one of the most critical and helpful sources of information concerning the development of two important drugs we were developing at Merck the statins, for control of LDL cholesterol, and Proscar, for treatment of benign prostate enlargement. Wilson was always available to wrestle with problems that often arise in drug development. I needed expert friends in those early days, and probably still do, says P. Roy Vagelos, M.D., former chairman, president, and chief executive officer of Merck & Co. and now chair of the board of Regeneron Pharmaceuticals.

Wilsons research included the study of cholesterol metabolism and steroid hormone action. The UTSouthwestern Medical School graduate and former National Institutes of Health (NIH) researcher earned international prominence for his investigations of testosterone including its formation from cholesterol as well as its metabolism and action. His efforts elucidated disorders resulting from genetic defects that lead to disruption in sex hormone biosynthesis with corresponding alteration in development.

Collaborations at UTSouthwestern with David Russell, Ph.D., professor of molecular genetics, led to the cloning of the 5-alpha-reductase (5AR) gene, development of animal models for 5AR deficiency, and eventually the finding that a 5AR inhibitor blocked prostate growth, which resulted in clinical trials led by Claus Roehrborn, M.D., chair of urology. The human androgen receptor later was cloned in 1989, allowing Wilson and colleagues to identify the receptor as a transcription factor that could regulate both the receptor and 5AR expression in prostate cancer. Other scientists at UTSouthwestern expanded upon his research, identifying androgen involvement in virtually all aspects of prostate development, alternate mechanisms of androgen synthesis, and other forms of androgens related to castrate-resistant prostate cancer.

Among his numerous awards, Wilson received the Kober Medal from the Association of American Physicians (1999); the Fred Conrad Koch Award from The Endocrine Society (1993); Gregory Pincus Award from the Worcester Foundation for Experimental Biology (1992); Henry Dale Medal from the Society for Endocrinology (1991); Amory Prize from the American Academy of Arts and Sciences (1977); and the Eugene Fuller Award from the American Urological Association. He was elected as a member of the American Academy of Arts and Sciences (1982), the National Academy of Sciences (1983), and the National Academy of Medicine (1994) as well as the American Philosophical Society and served as president of the Endocrine Society, the American Society for Clinical Investigation, and the Association of American Physicians.

Wilson, seen in 1992, was elected as a member of the American Academy of Arts and Sciences (1982), the National Academy of Sciences (1983), and the National Academy of Medicine (1994).

Wilson, who had held the Charles Cameron Sprague Distinguished Chair of Biomedical Research, was known as a collaborative colleague and empathetic adviser to students and fellows. His approach with students and trainees was threefold find out what they want to do, encourage them to do it, and develop pathways to fulfill their goals, he said in an interview with The Journal of Clinical Investigation. He also noted that some of the most difficult students to counsel turned out to be late bloomers who really were worth an investment of time and effort.

At UTSouthwestern, he served as the first director of the Medical Scientist Training Program, and it was recently announced that the Physician Scientist Training Program in Internal Medicine would be known as the Jean Wilson Society. The Jean D. Wilson Center for Biomedical Research and The Jean D. Wilson, M.D. Award, which honor excellence in scientific research mentorship, are named in his honor. The center was established with support from Dr. Wilson and his sister, the late Dr. Margaret Sitton, to promote research in endocrinology, developmental biology, and genetics, along with the J.D. and Maggie E. Wilson Distinguished Chair in Biomedical Research. In addition, he served among editors of two landmark medical textbooks Williams Textbook of Endocrinology and Harrisons Principles of Internal Medicine and as editor for The Journal of Clinical Investigation, among other journals. He authored The Memoir of a Fortunate Man, which chronicles his life growing up in the Texas Panhandle through his rise to pioneering academic physician and researcher.

Jean was a popular and highly sought-after attending physician on the wards of Parkland Memorial Hospital, valued for his vast expertise in endocrinology and medicine in general, say Nobel Laureates Joseph Goldstein, M.D, chair of molecular genetics, and Michael Brown, M.D., director of the Erik Jonsson Center for Research in Molecular Genetics and Human Disease. He founded a diabetic foot clinic at Parkland and spent hours each week clipping toenails and treating ulcers on the feet of elderly diabetic patients. After long days on the wards, he would retire to his modest laboratory where he would spend half the night meticulously dissecting rabbit fetuses. Often, when we were just starting our careers, we would sit by his side while he dissected, receiving sage advice about our careers as physician-scientists and life in general. Later, he extended his fatherly role to generations of M.D./Ph.D. students when he became the founding director of our M.D./Ph.D. program.

He had a rich life outside of the Medical Center as well. An avid opera buff, Wilson collected antique gramophones that could play every type of recording that had ever been produced. His extensive collection of 3,500 old 78-rpm operatic recordings included a 1917 disc of Enrico Caruso singing songs of Irving Berlin the only record that Caruso ever recorded in English, they note.

An avid opera buff, Wilson, seen in 2019, collected antique gramophones. His extensive collection of 3,500 old 78-rpm operatic recordings included a 1917 disc of Enrico Caruso singing songs of Irving Berlin the only record that Caruso ever recorded in English.

He took memorable trips to places like the North Pole, Antarctica, the Galapagos Islands, and the Easter Islands. He often incorporated science into his trips, visiting the Kangaroo Island in Australia to study sexual development in wallabies, and to Kenya to biopsy the phallus of the spotted hyena. Fearless in the pursuit of knowledge, he performed a rectal examination on a lion to estimate the size of the prostate, Goldstein and Brown say. A dedicated bird watcher, he traveled the world to many exotic places, hoping to spot that rare bird. But in the end, the rarest of that rare bird was Jean Wilson himself.

Born in Wellington, Texas, in 1932, Wilson obtained an undergraduate degree in chemistry from UT Austin and graduated from UTSouthwestern Medical School in 1955. As a student, he studied the control of urinary acid secretion by adrenal hormones, and as a resident, he investigated cholesterol metabolism. After residency, he spent two years at the NIH, where he studied ethanolamine biosynthesis. He joined the UTSouthwestern faculty in 1960 where he began his studies of testosterone, and worked in 1970 at Cambridge University. In all, he spent 60 years at UTSouthwestern and was named professor emeritus of UTSouthwesterns storied internal medicine department in 2011.

Jean Wilson leaves us with a remarkable legacy a quintessential physician-scientist whose scholarship both inspires and continues to serve as a foundation for new advances, says Podolsky, also professor of internal medicine.

In a career spanning six decades at UTSouthwestern, Dr. Jean Wilsons discoveries included:

Cholesterol metabolism

Dr. Wilson developed methods for quantifying cholesterol synthesis, absorption, degradation, and excretion in lab animals. Together, these analytical methods served as tools for understanding the feedback control of cholesterol synthesis and turnover. In addition, Dr. Wilson demonstrated that plasma cholesterol is synthesized in the intestinal wall and liver, findings that helped researchers define the contributions of diet and endogenous synthesis to cholesterol turnover in humans and other primates.

Male androgens

Concurrently, Dr. Wilson studied the action of male androgens, focusing on testosterone and its metabolite, dihydrotestosterone. Starting with a collaboration with his postdoctoral fellow, Nicholas Bruchovsky, in 1966, the researchers discovered that testosterone is converted inside prostate cells into dihydrotestosterone, a more potent androgen that is responsible for most of male sexual maturation and male sexual function. Dr. Wilson and his colleagues later showed that mutations that impair either the synthesis of testosterone, the conversion of testosterone to dihydrotestosterone, or the function of this metabolites receptor protein are the most common cause of birth defects associated with incomplete development of the male urogenital tract, affecting about four in every 1,000 boys. Cloning these responsible genes eventually allowed researchers to identify asymptomatic carriers of these mutations.

Dihydrotestosterone

Dr. Wilson also discovered that excess dihydrotestosterone is responsible for benign prostatic hyperplasia (BPH), or prostate enlargement, a condition that affects about 210 million men worldwide. Dihydrotestosterone is responsible for prostate growth in all male mammals, but in humans and dogs, prostate growth continues throughout life. Wilson and his colleagues showed that local excess of this potent androgen leads to prostate overgrowth. By curbing its production by inhibiting 5a-reductase, the enzyme that converts testosterone to dihydrotestosterone, they were able to prevent BPH in dog models of this condition. These findings have been developed into multiple 5a-reductase-inhibiting pharmaceuticals to treat this condition in human patients.

Brown, a Regental professor and director of the Erik Jonsson Center for Research in Molecular Genetics and Human Disease, holds The W.A. (Monty) Moncrief Distinguished Chair in Cholesterol and Arteriosclerosis Research, and the Paul J. Thomas Chair in Medicine.

Goldstein, a Regental professor and chair of molecular genetics, holds the Julie and Louis A. Beecherl, Jr. Distinguished Chair in Biomedical Research, and the Paul J. Thomas Chair in Medicine.

Podolsky holds the Philip OBryan Montgomery, Jr., M.D. Distinguished Presidential Chair in Academic Administration, and the Doris and Bryan Wildenthal Distinguished Chair in Medical Science.

Russell holds the Eugene McDermott Distinguished Chair in Molecular Genetics.

About UTSouthwestern Medical Center

UTSouthwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institutions faculty has received six Nobel Prizes, and includes 24 members of the National Academy of Sciences, 16 members of the National Academy of Medicine, and 13 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 2,800 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UTSouthwestern physicians provide care in about 80 specialties to more than 117,000 hospitalized patients, more than 360,000 emergency room cases, and oversee nearly 3 million outpatient visits a year.

Original post:
In Memoriam: Jean Wilson, M.D., made scientific discoveries that led to effective prostate treatments, insights into sexual differentiation - UT...

Congratulations! | East Tennessee 19-year-old headed to medical school – WBIR.com

When Blake Ivey graduated high school at 17 years old, he already had his associate's degree from Roane State Community College.

KNOXVILLE, Tenn. When most people turned 19 years old, they were likely just starting college or entering the workforce. One East Knoxville teen is way ahead of that, already headed to medical school.

Blake Ivey started taking college courses while in high school. He graduated when he was 17 years old, and already had his associate's degree from Roane State Community College in hand. After high school, he transferred to the University of Tennessee.

He graduated from UT in May. Now, he is headed to Lincoln Memorial University to get started with medical school.

He accomplished all this after being born to a single mother in rural Campbell County. It was his dream ever since he was young to become a doctor, he said.

He said he started dreaming about being a doctor after seeing his grandfather pass away from a heart attack in 2010, while on a road trip with his family.

"That's the worst feeling you can ever have, is not being able to help somebody. And that's the inspiration for why I want to become a physician because I want to be the person who is able to solve that problem, being able to help those in need," he said.

He will start studying at LMU in July. He'll go there 4 years, and then will need at least 3 years of training before he can officially become a doctor. He said he hopes to become a family physician, but also said he is keeping his options open.

"First and foremost, you need to be able to believe in yourself," he said. "Another thing is, anything is possible. You need to have confidence in yourself, you need to have that hard work ethic and be able to get a support system."

See more here:
Congratulations! | East Tennessee 19-year-old headed to medical school - WBIR.com